

Book now and save up to \$700

January 30 - February 1, 2017, **San Diego, CA**



PRECISION **LBx**

Summit

Translating Next Generation Liquid Biopsies into Clinical Reality

Defining the Roadmap for the Successful Clinical Application of Next Generation Liquid Biopsy Diagnostics

17 Expert Speakers, including:



Stefan Scherer
Vice President,
Global Head Correlative Science
Novartis



Thomas Schlange
Senior Scientist,
Bayer & EFPIA Coordinator,
IMI Cancer-ID



George Vasmatazis
Co-Director Biomarker Discovery Program
Mayo Clinic



Jean-Francois Martini
Senior Director, Translational
Oncology, EDTO Group
Pfizer

▲▲ A fantastic event both in terms of science and networking opportunities. Highly recommended to everybody working in the “biomarkers to diagnostics” field. ►►

**Biomarker & Diagnostics
Event Series Attendee**

www.lbx-summit.com

Tel: +1 212 537 5898 | Email: info@hansonwade.com

Precision LBx – Liquid Biopsy Diagnostics





Welcome to Precision LBx Summit

The Precision Medicine Initiative and Cancer Moonshot programs have placed non-invasive diagnostic testing at the forefront of the shifting personalized medicine paradigm. Liquid biopsies hold the potential to be **the holy grail of non-invasive diagnostics**, promising real time longitudinal patient monitoring and cost effective diagnostic screening.

With breakthrough successes in the low hanging fruit of NSCLC, now is the time to match the advances in technology platforms with evolving disease complexity to **drive forward the clinical utility of liquid biopsy testing**.

The Precision LBx Summit will bring together the leaders from **biopharma, academia** and **Dx developers** to build the annual platform that dictates the direction and rhetoric of the evolving liquid biopsy story.

Join this burgeoning community to assess the **scope and potential of fluid based biomarkers** and advance the utilization of non-invasive testing to **inform drug development and clinical decision making**.

Top 5 Reasons to Attend Precision LBx Summit

- 1** Analyze the cutting edge applications of liquid biopsies and how to prove their clinical utility with case studies from **Astrazeneca, Genentech, Mayo Clinic** and **Merck**
- 2** Understand the arsenal of biomarkers and biofluids and evaluate their potential as non-invasive diagnostics with insight from **Novartis** and **Eisai**
- 3** Challenge and debate how we overcome the lack of standardization and validation within the field alongside **Pfizer, TGen** and **Bayer**
- 4** Hear from **Pfizer** and **UCSD** as they share their secrets for advancing diagnostic technology to provide better, analysis and interpretation of biomarker data
- 5** Join the likes of **MD Anderson** and **Johns Hopkins** to define the roadmap for furthering the future impact of liquid biopsies in the evolving precision medicine paradigm

Hear What Previous Biomarker & Diagnostic Event Series Attendees Have to Say:

“Focused speakers allowed for **streamlined discussion and open conversation**. I left the meeting aligned on the latest developments and carried away clear messages.”

“Speed networking session is extremely useful! A mix of **professionals from clinics, diagnostics, research, pharma and technology providers**. Roundtable sessions were great!”

“A great balance between **pharma, industry and academia** and cover a broad range of **technical, regulatory and business issues** related to the advancement of personalized medicine. The meeting size is **just right for networking** and has a great mix in the variety of presentations.”





Speakers



Andrea Ferris
President &
Chairman
LUNGevery



Samir Hanash
Director, Red &
Charline McCombs
Institute for the Early
Detection & Treatment
of Cancer
**The University of
Texas MD Anderson
Cancer Center**



Hatim Husain
Assistant Professor
of Hematology-
Oncology
**UCSD Moores
Cancer Center**



Louise Laurent
Associate
Professor,
Department of
Reproductive
Medicine
UCSD



Yan Li
Senior Manager,
Oncology Dx
Development
Genentech



Jun Luo
Associate
Professor of
Urology
**Johns Hopkins
Medical
Institutions**



**Jean-Francois
Martini**
Senior Director,
Translational
Oncology, EDTO
Group
Pfizer



Dennis Merkle
Senior Director & Head
of Market Enabling
Technologies, Global
Early Development,
Clinical Biomarkers &
Companion Diagnostics
Merck



Pallavi Sachdev
Director, Oncology
Biomarker
Research Clinical
Development
Eisai



Thomas Schlange
Senior Biomarker
Scientist, **Bayer** &
EFPIA Coordinator
IMI Cancer-ID



**Steven Pirie-
Shepherd**
Director, Oncology
Translational
Research
Pfizer



Stefan Scherer
Vice President,
Global Head
Correlative Science
Novartis



Rebecca Suttman
Senior Scientific
Researcher
Genentech



Kenneth Thress
Director, Oncology
Translational Science
Astrazeneca



**Kendall Van
Keuren-Jensen**
Associate Professor,
Neurogenomics &
Co-Director, TGen
Center for Noninvasive
Diagnostics
**Translational
Genomics Research
Institute**



George Vasmataz
Co-Director
Biomarker Discovery
Program, Center
for Individualized
Medicine
Mayo Clinic



Lucy Xu
Associate Director,
Clinical Biomarker
Research
Eisai



Conference Day One | January 31, 2017

 Thomas Schlange Senior Biomarker Scientist, Bayer & EFPIA Coordinator, IMI Cancer-ID	8.50 Chair's Opening Remarks
Realizing the Potential Scope & Breadth of Liquid Biopsy Diagnostics	
 Stefan Scherer Vice President, Global Head Correlative Science, Novartis	9.00 An Overview of Liquid Biopsies: Where Do We Stand With its Clinical Impact? • Proving liquid biopsies can provide supporting and correlating data to standard biopsy samples • Why the time is now to drive forward the clinical applications of liquid biopsies • Where do the greatest opportunities lie in the next five years?
 Andrea Ferris President & Chairman, LUNgevity	9.30 A Patient Perspective on the Implementation of Liquid Biopsies in Healthcare • Understanding the patient need for non-invasive diagnostics • Patient considerations for developing liquid biopsy tests
 Hatim Husain Assistant Professor of Hematology- Oncology, UCSD Moore's Cancer Center	10.00 Assessing the Scope of Biofluids in Liquid Biopsy Diagnostics • Discussing the plethora of biofluids and their potential clinical use • What are the unique challenges with isolating biomarkers in different biofluids? • How alternative biofluids can provide complementary information to help inform clinical decision making
10.30 Morning Refreshments & Networking	
Overcoming Challenges to Improve the Predictiveness of Liquid Biopsy Biomarkers	
 Steven Pirie-Shepherd Director, Oncology Translational Research, Pfizer	11.15 The Evolving Role of Circulating Tumor Cells as Informative Biomarkers • What is the USP of the CTC in liquid biopsy? • How can CTCs be predictive biomarkers in liquid biopsy? • How to best integrate CTCs with other biomarker sources to provide the most informative and granular picture • How does CTC enumeration correlate with disease status for use as a diagnostic indicator?
 Lucy Xu Associate Director, Clinical Biomarker Research, Eisai	11.45 Converting the Hype into Reality: Realizing the Potential of Cell-Free DNA • Discussing strategies for delineating disease derived cell-free DNA from wild type noise • How truly reflective of disease is cell-free DNA? • Developing the use of cell-free DNA as a biomarker for drugs targeting differential expression • Discussing the use of cell-free DNA for measuring mutational load and proactively predicting patient response
 Samir Hanash Director, Red & Charline McCombs Institute for the Early Detection & Treatment of Cancer, The University of Texas MD Anderson Cancer Center	12.15 Investigating & Evaluating Non-DNA Approaches for Liquid Biopsies • Assessing the value of extracellular RNA as a predictive biomarker • Evaluating biomarkers for the study of proteomics, lipidomics and metabolomics • Presenting a multiomic approach to produce a more granular picture of disease to improve clinical decision making



Kendall Van Keuren-Jensen
Associate Professor,
Neurogenomics &
Co-Director, TGen
Center for Noninvasive
Diagnostics,
**Translational Genomics
Research Institute**

12.45 Using exRNA to Monitor the Central Nervous System

- Discussing the presence of RNA in body fluids and its relative stability when transported via extracellular vesicles or carrier proteins
- Identification of CNS-enriched transcripts in saliva, plasma/serum, urine and cerebrospinal fluid
- Examining the potential of extracellular RNA for monitoring CNS diseases

1.15 Lunch & Networking

Optimizing Technology: Standardization & Validation of Liquid Biopsy Tests



Thomas Schlange
Senior Biomarker
Scientist, **Bayer**
& EFPIA
Coordinator,
IMI Cancer-ID

2.15 Why We Need Standardization in the Liquid Biopsies Field

- Overcoming the reproducibility of data crisis
- Defining "prove": what is required to prove clinical utility?
- How can we robustly and universally standardize liquid biopsy testing?



Steven Pirie-Shepherd
Director, Oncology
Translational
Research, **Pfizer**

2.45 Panel Discussion: Standardizing & Validating Liquid Biopsy Diagnostics

- Discussing the need to show the ability of liquid biopsy data to enable successful clinical decision making
- How do we best validate liquid biopsy technology and data to ensure clinical utility?
- Improving the quantification of longitudinal data to link disease burden with a clinical response
- Standardizing and optimizing protocols from sample collection to downstream data analysis: Building the complete workflow from patient sample to actionable information
- Discussing standardizing the capture and processing of CTCs and exosomes



Kendall Van Keuren-Jensen
Associate Professor,
**Translational
Genomics Research
Institute**

3.45 Afternoon Refreshments & Networking

4.15 Breakout Roundtable Discussions

1

What are the promises and limitations of the next generation of liquid biopsy tests?

2

Addressing challenges in the commercialization of economically viable liquid biopsy diagnostics

3

How do we educate and challenge pathologists and clinicians to increase the adoption of liquid biopsy testing?



Jun Luo, Associate Professor of Urology,
Johns Hopkins Medical Institutions



Dennis Merkle, Senior Director & Head of
Market Enabling Technologies, Global Early
Development, Clinical Biomarkers & Companion
Diagnostics, **Merck**



Thomas Schlange
Senior Biomarker
Scientist, **Bayer** &
EFPIA Coordinator,
IMI Cancer-ID

5.15 Chair's Closing Remarks

5.20 Close of Day 1



Conference Day Two | February 1, 2017



Thomas Schlange
Senior Biomarker
Scientist, **Bayer** &
EFPIA Coordinator,
IMI Cancer-ID

8.50 Chair's Opening Remarks

Advancing the Clinical Applications of Liquid Biopsy Testing



Dennis Merkle
Senior Director &
Head of Market
Enabling
Technologies,
Global Early
Development,
Clinical
Biomarkers &
Companion
Diagnostics,
Merck

9.00 Advances in Liquid Biopsy Technologies in Oncology Molecular Diagnostics

- Analyzing the patient benefits of liquid biopsies from rapid initiation of testing to rapid result reporting and therapy initiation
- Assessing the monitoring of patient mutation status during therapy to provide novel opportunities to tailor treatment
- Leveraging these diagnostics as life cycle management tools for both novel and mature targeted therapeutics



Kenneth Thress
Director, Oncology
Translational
Science,
Astrazeneca

9.30 Plasma Genotyping in Osimertinib Clinical Trials: Patient Selection & Mechanisms of Resistance

- More information to follow



George Vasmatazis
Co-Director
Biomarker
Discovery
Program, Center
for Individualized
Medicine, **Mayo
Clinic**

10.00 Harnessing Liquid Biopsies for Real Time Longitudinal Disease Monitoring to Rapidly Inform Therapy Resistance, Treatment Selection & Disease Recurrence

- Longitudinally studying the evolution of mutations and genomic alterations to find actionable information to handle recurrence
- Identification of treatment influenced mutations to ensure more tailored and rapid therapeutic decisions
- Strategies for overcoming background noise and sensitivity issues to identify nuances in patient responses
- Monitoring disease burden progression and recurrence to inform treatment regimes

10.30 Morning Refreshments & Networking



Yan Li
Senior Manager,
Oncology Dx
Development,
Genentech

11.00 LBx for CDx: Developing Liquid Biopsies as Companion Diagnostics

- A look at how advances in non-invasive liquid biopsies are revolutionizing patient selection
- Evaluating the potential of liquid biomarker driven drug development and liquid biopsy based companion diagnostics
- Case study: The development of the cobas® EGFR Mutation Test v2



Jun Luo
Associate
Professor of
Urology,
**Johns Hopkins
Medical
Institutions**

11.30 Treatment-Specific Liquid Biopsy Markers in Advanced Prostate Cancer

- Introducing prostate cancer biology and the treatment landscape relevant to the development of liquid-based markers
- Case study: discovery, development, and implementation of AR-V7 as an actionable liquid biopsy marker
- Discussion of approaches to explore the full potential of liquid biopsies in prostate cancer



Rebecca Suttman
Senior Scientific
Researcher,
Genentech

12.00 Retrospective Analysis of CellSearch CTC Enumeration Data Across Clinical Trials

- Processing of CTCs from over 10,000 clinical trial samples
- Analyzing prevalence across multiple cancer indications
- Elucidating associations with response and progression within the dataset



12.30 Lunch & Networking



George Vasmatazis
Co-Director Biomarker
Discovery Program,
Center for
Individualized
Medicine,
Mayo Clinic



Kenneth Thress
Director, Oncology
Translational Science,
Astrazeneca



Yan Li
Senior Manager,
Oncology Dx
Development,
Genentech



Hatim Husain
Assistant Professor of
Hematology-Oncology
**UCSD Moores Cancer
Center**

1.30 Panel Discussion: Demonstrating the Data to Prove the Clinical Utility of Liquid Biopsy Diagnostics

- How close are we to utilizing liquid biopsy for the classification of patients?
- What does normal variability in data look like and how do we develop personalized baselines to ensure accuracy of decision making?
- Where does the most clinical value lie for liquid biopsies?
- Do we have the infrastructure in place to support the widespread implementation of liquid biopsy testing in the clinic?
- Where is the clinical value in utilizing liquid biopsies for non-targeted therapies?
- How do we translate great biological research into bona fide clinical utility?
- Creating the most efficient and effective collection of mutation targets for liquid biopsy monitoring: what markers should we be going after?
- Can we produce platforms sensitive enough to predict early disease manifestation?
- Realism vs. idealism: how sensitive do we need to be for appropriate clinical utility?

Developing Downstream Technology to Enhance the Clinical Utility of Liquid Biopsy Tests



Jean-Francois Martini
Senior Director,
Translational
Oncology, EDTO
Group, **Pfizer**

2.15 Use of Circulating Free DNA in Clinical Trials: Challenges & Opportunities

- Analyzing the use of cfDNA for patient characterization in clinical trial utilizing dPCR
- Applying NGS platforms to cfDNA analysis in clinical specimens
- How to integrate dPCR and NGS technologies to improve the clinical utility of liquid biopsy tests



Louise Laurent
Associate
Professor,
Department of
Reproductive
Medicine,
UCSD

2.45 Evaluating the Utilization of NGS for Liquid Biopsy Diagnostics

- Developing NGS applications to provide better resolution in the study of whole genomes, exomes and transcriptomes to identify more nuanced changes in mutational frequency
- The depth vs. cost conundrum: powering NGS technology to get ideal coverage and depth of multiple genes
- Creating high efficiency, reproducible sequencing libraries from low quantity samples
- How deep is deep enough for NGS applications in liquid biopsy?



Pallavi Sachdev
Director, Oncology
Biomarker Research
Clinical Development,
Eisai

3.15 Customizing Liquid Biopsy Applications for Exploratory Biomarker Research as well as Diagnostic Strategies

- Addressing the true value for utilizing liquid biopsy in exploratory biomarker research - Detailing key areas of consideration for developing liquid biopsy diagnostic strategies



Thomas Schlange
Senior Biomarker
Scientist, **Bayer** &
EFPIA Coordinator,
IMI Cancer-ID

3.45 Chair's Closing Remarks

4.00 Close of Precision LBx Summit & Afternoon Refreshments



Workshop A

The Future Impact of Liquid Biopsy in Precision Medicine

Date: January 30, 2017 | Time: 10am-1pm

We are gaining real traction in harnessing the application of liquid biopsy testing in the clinical setting, with the most success seen in plasma based companion diagnostics in NSCLC. However, the industry agrees that this is the low hanging fruit, and the potential impact of non-invasive diagnostics is further reaching.

This in-depth, discussion lead workshop will tackle holistically **how liquid biopsy can transform precision medicine** and how we can reach the "holy grail" that is population screening.

Key themes to include:

- What will the precision medicine arena look like over the next 5-10 years with the fast developing applications of liquid biopsies?
- Discussing the potential impact of liquid biopsy for screening of prodromal and healthy populations: how do we reach this holy grail?
- How far have we come and what do we need to do in order to continue the integration of liquid biopsies into the precision medicine paradigm?



Workshop leader

Samir Hanash, Director, Red & Charline McCombs Institute for the Early Detection & Treatment of Cancer, **The University of Texas MD Anderson Cancer Center**

Samir Hanash is Director, Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, and Professor, Department of Clinical Cancer Prevention -The University of Texas MD Anderson Cancer Center.

Samir received his M.D. from the American University of Beirut and his Ph.D. in Human Genetics from The University of Michigan.

Great networking opportunities.
The talks were very informative
and well presented. I had access to
number of important KOL's

**Biomarker & Diagnostics Event
Series Attendee**



It was the first meeting that I
attended where I could talk to
just different levels of persons
all open for discussion. Best
meeting I have ever attended.

**Biomarkers & Diagnostics Event
Series Attendee**




Partnership Opportunities

Why Partner

The Precision LBx Summit 2017 will bring together the key opinion leaders and influencers from the liquid biopsy field. Uniting big pharma, biotech, Dx developers, leading cancer centers, academic institutes, regulators and payors, to advance the development and application of next generation liquid biopsy diagnostics.

The summit will help you **align your Dx technology with the needs of pharma and healthcare, showcasing the clinical utility of your platform**. You'll discover what solutions the liquid biopsy field need and ascertain the scope for potential opportunity to advance the development and positioning of next generation platforms.

You'll Meet People From...



* Based on previous Hanson Wade Biomarker & Diagnostic event series meetings

What Does a Commercial Partnership Look Like at Precision LBx Summit?

We tailor bespoke business development solutions to suit your commercial objectives. Do you have an innovative non-invasive diagnostic platform with the data to back up its clinical utility? We're looking to partner with you. Here's a snapshot of partnership opportunities:

- **Lead Partner** – 30 minute plenary presentation to the entire audience, panel/roundtable position, exclusive top-tier branding, exhibition space, private hosting option and passes
- **Expertise Partner** – 30 minute plenary presentation to the entire audience, branding, exhibition space and passes
- **Innovation Partner** – 10 minute presentation to the entire audience, branding, exhibition space and passes
- **Hosting Options** – Exclusive ownership of a bespoke option upon request (eg. Drinks Reception, Private Lunch or Dinner, Site Visit)
- **Exhibition Partner** – Physically showcase technology and increase your brand exposure with an exhibition space

Become a Precision LBx Summit Commercial Partner

Contact

Sam Sarwar

Commercial Director

Tel: +1 212 537 5898

Email: sponsor@hansonwade.com





Pricing

Register

www.lbx-summit.com/register

Tel: +1 212 537 5898

Email: register@hansonwade.com

Mail:

Hanson Wade,
4th Floor,
52 Grosvenor Gardens,
London,
SW1W 0AU

Team Discounts*

- **10% discount** – 3 delegates
- **15% discount** – 4 delegates
- **20% discount** – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Team discounts are not applicable to academic pricing.

Top 3 Benefits of Attending

1

Understand the limitations and potential of a multitude of biomarkers and biofluids for use as clinical indicators

2

Define your roadmap for successfully developing and implementing clinically useful liquid biopsy diagnostics

3

Be part of the exclusive community of industry experts championing the utilization of non-invasive diagnostics

Industry Pricing

	Register & Pay before Friday November 4, 2016 (Save up to \$700!)	Register & Pay before Friday December 9, 2016 (Save up to \$500!)	Register & Pay before Friday January 6, 2017 (Save up to \$300!)	Standard Prices
Conference Only	\$2099	\$2299	\$2499	\$2699
Conference + 1 Workshop	\$2698	\$2898	\$3098	\$3198
Workshop Only	\$699			

Academic Pricing

	Register & Pay before Friday November 4, 2016 (Save up to \$400!)	Register & Pay before Friday December 9, 2016 (Save up to \$300!)	Register & Pay before Friday January 6, 2017 (Save up to \$200!)	Standard Prices
Conference Only	\$1299	\$1399	\$1499	\$1599
Conference + 1 Workshop	\$1698	\$1798	\$1898	\$1998
Workshop Only	\$499			


Venue

Marriott Marquis San Diego Marina

333 West Harbor Drive
San Diego, California
92101
USA

www.marriott.com/hotel

Please note: Overnight accommodation and travel are not included in the registration fee.



Great meeting with decision makers and scientists mixing well. Perfect networking opportunities with true value!

**Biomarker & Diagnostics
Event Series Attendee**

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH